First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?
Loading...
Embargo End Date
ICR Authors
Authors
Napolitano, A
Huang, PH
Jones, RL
Huang, PH
Jones, RL
Document Type
Journal Article
Date
2024-10-01
Date Accepted
2024-07-10
Abstract
The optimal medical treatment of chemotherapy-ineligible patients affected by advanced soft-tissue sarcomas is unclear. In this population, tyrosine kinase inhibitors represent an appealing alternative treatment strategy. First-line use of the tyrosine kinase inhibitor anlotinib in chemotherapy-ineligible patients with soft-tissue sarcoma showed promising activity across multiple histologies. See related article by Li et al., p. 4310.
Citation
Clinical Cancer Research, 2024, 30 (19), pp. 4257 - 4259
Source Title
Clinical Cancer Research
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265